secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001999371-25-006473
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction
--------------------------------------------------------------------------------

- Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.
- Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.
- Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.
- Topline results expected in the second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/0001999371-25-006473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/tnxp-8k_052125.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-006473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer